varisacumab
Varisacumab is an investigational monoclonal antibody that binds to the vascular endothelial growth factor A (VEGF-A) and selectively inhibits the activation of VEGF receptor 2 (VEGFR-2). VEGF-A modulates both tumor angiogenesis and immune cell trafficking.
varisacumab

Varisacumab is an investigational monoclonal antibody that binds to the vascular endothelial growth factor A (VEGF-A) and selectively inhibits the activation of VEGF receptor 2 (VEGFR-2). VEGF-A modulates both tumor angiogenesis and immune cell trafficking.

 

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Click here to review our Privacy Policy.